A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease.

Fernando González-OrtizPamela C L FerreiraArmand González-EscalanteLaia Montoliu-GayaPaula Ortiz-RomeroPrzemyslaw R KacMichael TurtonHlin KvartsbergNicholas J AshtonHenrik ZetterbergPeter HarrisonBruna BellaverGuilherme PovalaVictor L VillemagneTharick A PascoalMary GanguliAnne D CohenCarolina MinguillonJose ContadorMarc Suárez-CalvetThomas K KarikariKaj Blennow

Published in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2023)

UGOT p-tau217 can be an easily accessible and efficient way to screen and monitor patients with suspected AD pathophysiology, even in the early stages of the continuum.

Keyphrases

cognitive decline
mild cognitive impairment
high throughput
cerebrospinal fluid
gold nanoparticles
quantum dots
high resolution
physical activity
molecularly imprinted
single cell
tandem mass spectrometry
simultaneous determination